Danaher to Acquire Masimo for $9.9B to Enter Hospital Patient‑Monitoring; Legal Probe Raised

Danaher targets hospital patient-monitoring with Masimo acquisition

Danaher is moving to broaden its diagnostics footprint by agreeing to buy medical-technology firm Masimo, a move that centers on acquiring Masimo’s hospital-focused pulse oximetry and patient‑monitoring hardware. The deal, valued by Danaher at about $9.9 billion enterprise value including assumed debt and net acquired cash, is positioned as a strategic entry into bedside monitoring that the buyer says will accelerate its diagnostics growth. Danaher plans to finance the transaction with cash and debt and projects the acquisition to be accretive to adjusted diluted net earnings per share by $0.15–$0.20 in the first full year and roughly $0.70 five years after close.

Masimo’s portfolio of sensors and bedside monitors is expected to complement Danaher’s existing life‑science tools and diagnostics platforms, according to company projections that forecast high‑single‑digit core revenue growth for the business over the long term. Danaher models the purchase at about 18 times estimated 2027 EBITDA and aims to bring that multiple closer to 15 times through cost and revenue synergies. Management highlights potential cross‑selling opportunities, scaling of manufacturing and supply‑chain efficiencies as means to realise those synergies, while also positioning the combined business to address growing demand for continuous patient monitoring in hospitals.

The proposed combination raises integration and strategic‑fit questions within medtech circles because Masimo’s hospital hardware sits somewhat outside Danaher’s traditional diagnostics and life‑science tools focus. Industry analysts say execution risk centers on integrating a device‑centric business with Danaher’s diagnostics and instruments portfolio and on delivering the cost savings and revenue acceleration needed to justify the valuation. The companies are presenting the deal as a way to strengthen Danaher’s presence in clinical settings where real‑time monitoring data increasingly drives diagnostics and care decisions.

Activist campaign helps precipitate sale

The agreement follows a two‑year governance shift at Masimo after an activist proxy contest led by Politan Capital Management removed founder Joe Kiani as board chair, a change that industry observers say helps explain why Masimo engages on a sale now. The episode underscores how activist pressure can accelerate strategic reviews and transactional outcomes in medtech.

Law firm probes potential deal issues

Halper Sadeh LLC says it is investigating whether the transaction raises federal securities or fiduciary concerns and whether insiders received preferential treatment, signalling potential shareholder litigation or demands for additional disclosures if problems surface. The firm is soliciting affected shareholders to discuss possible remedies.